p22phox confers resistance to cisplatin, by blocking its entry into the nucleus

Cisplatin (CDDP) is a potent chemotherapeutic agent but resistance to the drug remains a major challenge in cancer treatment. To evaluate the efficacy of CDDP in oral squamous cell carcinoma (OSCC), we found that p22phox was highly expressed in CDDP-resistant OSCC specimens. Knockdown of p22phox sen...

Descripción completa

Detalles Bibliográficos
Autores principales: Hung, Chih-Chang, Chien, Chen-Yu, Chiang, Wei-Fan, Lin, Chang-Shen, Hour, Tzyh-Chyuan, Chen, Hau-Ren, Wang, Ling-Feng, Ko, Jenq-Yuh, Chang, Chi-Hua, Chen, Jeff Yi-Fu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414176/
https://www.ncbi.nlm.nih.gov/pubmed/25686830

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414176/
https://www.ncbi.nlm.nih.gov/pubmed/25686830

Ejemplares similares